
May 29, 2026
Samsung Bioepis Launches OPUVIZ Biosimilar in Europe
Samsung Bioepis has introduced OPUVIZ, a new biosimilar in Europe that references the well-known Eylea (aflibercept). This launch represents the fifth biosimilar product from Samsung Bioepis, following a recent introduction of a biosimilar referencing Stelara (ustekinumab) in Japan. The company aims to enhance patient access to ophthalmology treatments with OPUVIZ, as highlighted by Antonio Rito, Vice President and Head of Europe at Samsung Bioepis. He emphasized the importance of collaborating









